Journal
MARINE DRUGS
Volume 17, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/md17090518
Keywords
fucoidan; PGC-1 alpha; Parkinson's disease; mitochondrial dysfunction
Categories
Funding
- National Foundation - Korean government [NRF-2016R1D-1A3B01007727, NRF-2017M3A9B4032528]
Ask authors/readers for more resources
Mitochondria are considered to be the powerhouses of cells. They are the most commonly damaged organelles within dopaminergic neurons in patients with Parkinson's disease (PD). Despite the importance of protecting neuronal mitochondria in PD patients, the detailed mechanisms underlying mitochondrial dysfunction during pathogenesis and pathophysiological progression of PD have not yet been elucidated. We investigated the protective action of fucoidan against the detrimental action of 1-methyl-4-phenyl-pyridinium (MPP+), a neurotoxin used to model PD, in the mitochondria of SH-SY5Y neural cells. Fucoidan increased the expression of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) and protected the cells from MPP+-induced apoptosis by upregulating the 5 ' adenosine monophosphate-activated protein kinase (AMPK)-PGC-1 alpha axis. These effects were blocked by the silencing of the PGC-1 alpha axis. These results indicated that fucoidan protects SH-SY5Y cells from mitochondrial dysfunction and cell death caused by MPP+ treatment, via the AMPK-PGC-1 alpha axis. These findings also suggest that fucoidan could potentially be used as a therapeutic agent for PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available